91-81-6 Usage
Description
Tripelennamine, also known as pelanin and pyribenzamine, is an antihistamine drug used for treating various allergic conditions. It works by blocking the action of histamine, a substance released during an allergic response, thereby providing relief from symptoms.
Uses
Used in Medicine:
Tripelennamine is used as an antihistamine for treating allergic symptoms, such as itching, swelling, and redness. It is also used for conditions like rhinitis and conjunctivitis, which are characterized by inflammation and irritation in the nasal and eye areas, respectively.
Additionally, Tripelennamine is used for managing anaphylactic reactions, which are severe and potentially life-threatening allergic responses. By reducing the effects of histamine, it helps to alleviate the symptoms and prevent complications associated with these reactions.
Furthermore, Tripelennamine is also used for sunburn treatment, as it can help to soothe the skin and reduce inflammation caused by overexposure to the sun. This makes it a useful agent in providing relief and promoting healing for sunburned skin.
Originator
Pyribenzamine,Ciba,US,1946
Manufacturing Process
46 g of α-benzylaminopyridine in 50 cc of dry toluene are heated to 80°C [the
α-benzylaminopyridine may be obtained either according to the method of
Tchitchibabine and Knunjanz, Berichte, 64, 2839 (1931), which consists in
warming α-aminopyridine with benzaldehyde in formic acid, or alternatively by
the action of benzyl chloride on sodio-α-aminopyridine]. To the toluene
solution there are added gradually 9.5 g of 85% sodamide. After evolution of
ammonia, the major part of the toluene is distilled off; into the pasty mass
which remains there are poured 120 cc of an ethereal solution of 27 g of
dimethylaminochloroethane.
The mixture is heated until the temperature reaches 140°C, the ether distilling
out, then finally heated under reduced pressure (150 mm Hg) for 1/2 hour.
The mass is taken up with dilute hydrochloric acid and ether, neutralized at pH
7, and α-benzylaminopyridine separates. After making alkaline, using excess of potash, it is extracted with benzene, dried and distilled. The product
thereby obtained, dimethylamino-ethyl-N-benzyl-N-α-arninopyridine, boils at
135° to 190°C/1.7 mm, according to US Patent 2,502,151.
Therapeutic Function
Antihistaminic
Reactivity Profile
Tripelennamine neutralizes acids in exothermic reactions to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen may be generated in combination with strong reducing agents, such as hydrides.
Health Hazard
SYMPTOMS: Symptoms of exposure to Tripelennamine may include euphoria, aplastic anemia, excitement, hallucinations, ataxia, incoordination, athetosis, convulsions, postictal depression, dry mouth, fixed dilated pupils, flushing of the face, fever, central nervous system depression, drowsiness and coma.
Fire Hazard
Flash point data for Tripelennamine are not available. Tripelennamine is probably combustible.
Safety Profile
Poison by ingestion and
intraperitoneal routes. Human mutation data
reported. Has been implicated in aplastic
anemia. Used as an antdustasnine. Addicts
have added it to paregoric to make "blue
velvet," whtch can cause euphoria by
injection. When heated to decomposition it
emits toxic fumes of NOx.
Synthesis
Tripelennamine, N-benzyl-N′,N′-dimethyl-N-2-pyridylethylenediamine
(16.1.6), is synthesized by reacting 2-benzylaminopyrridine (16.1.5) with 2-dimethylaminoethylchloride
in the presence of sodium amide. 2-Benzylaminopyrridine, in turn,
can be easily synthesized by reduction of a Schiff base, synthesized by condensation of
2-aminopyrridine with benzaldehyde.
Metabolic pathway
When pyribenzamine is
incubated with rat liver microsomes, it is metabolized via N-oxide formation and
N-dealkylation which includes removal of the
dimethylamino moiety, the thiophenylmethyl moiety of
methaphenilene, and the benzyl moiety of
pyribenzamine.
Check Digit Verification of cas no
The CAS Registry Mumber 91-81-6 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 9 and 1 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 91-81:
(4*9)+(3*1)+(2*8)+(1*1)=56
56 % 10 = 6
So 91-81-6 is a valid CAS Registry Number.
InChI:InChI=1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3
91-81-6Relevant articles and documents
Nickel-Catalyzed Intramolecular Desulfitative C - N Coupling: A Synthesis of Aromatic Amines
Chen, Xuemeng,Jia, Xiuwen,Kramer, S?ren,Li, Yue,Lian, Zhong,Liu, Jiangjun,Sun, Haotian
, p. 5702 - 5711 (2020/05/19)
A nickel-catalyzed intramolecular C - N coupling reaction via SO2 extrusion is presented. The use of a catalytic amount of BPh3 allows the transformation to take place under much milder conditions (60 °C) than previously reported C - N coupling reactions by CO or CO2 extrusion (160-180 °C). In addition, this method displays good functional group tolerance and versatility, as it can be applied to the synthesis of dialkyl aryl amines, alkyl diaryl amines, and triaryl amines. The robustness of the desulfitative C - N coupling is demonstrated by three high-yielding gram-scale reactions.
Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction
Gogate, Priyanka N.,Ethirajan, Manivannan,Kurenova, Elena V.,Magis, Andrew T.,Pandey, Ravindra K.,Cance, William G.
, p. 154 - 156 (2014/05/20)
Focal adhesion kinase (FAK) and vascular endothelial growth factor receptor 3 (VEGFR3) are tyrosine kinases, which function as key modulators of survival and metastasis signals in cancer cells. Previously, we reported that small molecule chlorpyramine hydrochloride (C4) specifically targets the interaction between FAK and VEGFR3 and exhibits anti-tumor efficacy. In this study, we designed and synthesized a series of 1 (C4) analogs on the basis of structure activity relationship and molecular modeling. The resulting new compounds were evaluated for their binding to the FAT domain of FAK and anti-cancer activity. Amongst all tested analogs, compound 29 augmented anti-proliferative activity in multiple cancer cell lines with stronger binding to the FAT domain of FAK and disrupted the FAK-VEGFR3 interaction. In conclusion, we hope that this work will contribute to further studies of more potent and selective FAK-VEGFR3 protein-protein interaction inhibitors.